ImmunoGen Reports Recent Progress and Third Quarter 2018 Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/8/2026
- Fiserv president resigns, interim leaders named for financial unit
- Nasdaq sinks as AI worries hit chipmakers
- Amazon launches bond sale seeking at least $25 billion
- Raymond James Starts SpaceX (SPCX) at Strong Buy, PT Street High $800
- Exclusive-China's DeepSeek developing its own AI chip, sources say
Immunogen (IMGN) Reports In-Line Q3 EPS, Revenues Miss; Offers FY18 Revenue Outlook Below Consensus
November 2, 2018 6:36 AM EDTImmunogen (NASDAQ: IMGN) reported Q3 EPS of ($0.32), in-line with the analyst estimate of ($0.32). Revenue for the quarter came in at $10.93 million versus the consensus estimate of $13.06 million.
With the completion of enrollment in FORWARD I, we have initiated the activities required to support a BLA filing and launch mirvetuximab... More
